Lyell Immunopharma, Inc. Common Stock (LYEL)
PHARMACEUTICAL PREPARATIONS
Lyell Immunopharma, Inc. Common Stock (LYEL) is listed on Nasdaq, where it has traded since June 17, 2021.
- Listed On
- Nasdaq
- Listed Since
- June 17, 2021
- Employees
- 161
- Market Cap
- $240M
About Lyell Immunopharma, Inc. Common Stock
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 84 institutions reported holding LYEL, with 12.7 million shares worth $178.0 million in aggregate. The largest reported holder was Arch Venture Management, with 3.2 million shares worth $45.5 million. Of the 5 largest holders listed below, 2 added shares and 3 held their positions unchanged during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Arch Venture Management | 3,247,162 | $46M | Unchanged |
| Gsk | 1,512,659 | $21M | Unchanged |
| Vanguard | 976,925 | $14M | Added 17.24% |
| Orland Properties | 754,698 | $11M | Unchanged |
| BlackRock | 724,342 | $10M | Added 277.62% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is LYEL?
Lyell Immunopharma, Inc. Common Stock (LYEL) is listed on Nasdaq, where it has traded since June 17, 2021.
Who are the largest institutional holders of LYEL?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of LYEL were Arch Venture Management, Gsk and Vanguard.
How many institutions own LYEL?
84 institutions reported a position in LYEL for the quarter ended June 30, 2026, worth $178.0 million in total.
Did institutions buy or sell LYEL last quarter?
Of the 5 largest reported holders, 2 added shares and 3 held their positions unchanged during the quarter. Every reported holder and its change is on the SentiSense ownership page for LYEL.
Every reported institutional holder, plus insider and congressional trades in LYEL, on SentiSense.